Clinical Trials Using Abiraterone Acetate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Abiraterone Acetate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-39 of 39

  • Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

    The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.
    Location: Duke University Medical Center, Durham, North Carolina

  • Abiraterone and Prednisone without Hormone Therapy in Treating Patients with Metastatic Prostate Cancer

    This phase II trial studies how well abiraterone acetate and prednisone work without hormone therapy in treating patients with prostate cancer that has spread to other places in the body. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Prednisone is used to lessen inflammation and lower the body's immune response. When abiraterone acetate and prednisone are used, hormone injections are usually continued to maintain a low testosterone level in the blood. This study is being done to find out whether giving abiraterone acetate and prednisone without hormone injections would maintain lower levels of testosterone in the blood in patients with prostate cancer.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • GnRH analog, Abiraterone Acetate, and Prednisone in Treating Patients with Stage IV Castration Sensitive Prostate Cancer

    This phase Ib trial studies how GnRH analog, abiraterone acetate, and prednisone work in treating patients with stage IV castration sensitive prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as GnRH analog, abiraterone acetate, and prednisone may lessen the amount of androgen made by the body.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants with Metastatic Castration Resistant Prostate Cancer

    This phase II trial studies how well apalutamide and abiraterone acetate work in treating participants with castration resistant prostate cancer that has spread to other places in the body. Abiraterone acetate and apalutamide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as prednisone, is used to decrease the body’s immune response and may improve bone marrow function. Giving apalutamide, abiraterone acetate, and prednisone may work better in treating participants with castration resistant prostate cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Prednisone, Abiraterone, Cabazitaxel, and Enzalutamide in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase I trial studies the side effects and best dose of cabazitaxel when given together with prednisone, abiraterone, and enzalutamide in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Prednisone is an orally given steroid drug that helps in blocking some side effects of abiraterone. Abiraterone may lower the level of testosterone and enzalutamide may block the action of testosterone and these actions will prevent the growth of prostate cancer. Drugs used in chemotherapy, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving prednisone, abiraterone, cabazitaxel, and enzalutamide may work better in treating patients with castration-resistant cancer.
    Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

  • Androgen Deprivation Therapy, Pembrolizumab, and Stereotactic Body Radiation Therapy with or without TLR9 Agonist SD-101 in Treating Patients with Metastatic Prostate Cancer

    This randomized phase II trial studies how well androgen deprivation therapy, pembrolizumab, and stereotactic body radiation therapy with or without TLR9 agonist SD-101 in treating patients with prostate cancer that has spread to other places in the body. Androgen can cause the growth of tumor cells. Androgen deprivation therapy, such as leuprolide acetate, prednisone, and abiraterone acetate may lessen the amount of androgen made by the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Colony-stimulating factors, such as TLR9 agonist SD-101, may increase the production of blood cells. It is not yet known whether giving androgen deprivation therapy, pembrolizumab, and stereotactic body radiation therapy with or without TLR9 agonist SD-101 may work better in treating patients with prostate cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Apalutamide with or without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients with High-Risk Prostate Cancer Undergoing Surgery

    This randomized phase II trial studies how well apalutamide works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate cancer undergoing surgery. Androgen can cause the growth of prostate cancer cells. Hormone therapy using apalutamide, abiraterone acetate, and gonadotropin-releasing hormone analog (GnRH agonist) may fight prostate cancer by lowering the levels of androgen the body makes. Prednisone may either kill the tumor cells or stop them from dividing. Giving apalutamide with or without abiraterone acetate, GnRH agonist and prednisone may work better in treating patients with prostate cancer.
    Location: 2 locations

  • Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients with Castration-Resistant Prostate Cancer

    This phase II trial studies the side effects and how well abiraterone acetate, niclosamide, and prednisone work in treating patients with castration-resistant prostate cancer. Androgens can cause the growth of prostate cells. Hormone therapy using abiraterone acetate may fight prostate cancer by lowering the amount of androgen the body makes. Niclosamide is a drug that may block another signal that can cause prostate cancer cell growth. Prednisone is a drug that can help lessen inflammation. Giving abiraterone acetate, niclosamide, and prednisone may be a better treatment for patients with castration-resistant prostate cancer.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

    This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate), six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

    This multicenter, international, Phase Ib / II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of GDC-0980 administrated in combination with abiraterone (this phase is no longer active), a Phase II, 3-arm, double-blind, randomized comparison of ipatasertib with abiraterone and prednisone / prednisolone versus placebo with abiraterone and prednisone / prednisolone and a safety single-arm, open-label cohort of ipatasertib 400 mg daily alone or in combination with prednisone / prednisolone or prednisone / prednisolone plus abiraterone.
    Location: See Clinical Trials.gov

  • Fluciclovine (FACBC) PET / CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

    This phase II trial studies how well fluciclovine positron emission tomography (PET) / computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. Fluciclovine PET / CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Antiandrogen Therapy and SBRT in Treating Patients with Recurrent, Metastatic Prostate Cancer

    This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and has spread to other parts of the body. Drugs used in chemotherapy, such as leuprolide, apalutamide, and abiraterone acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving antiandrogen therapy and SBRT may work better in treating patients with prostate cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Antiandrogen Therapy, Abiraterone Acetate, and Prednisone with or without Neutron Radiation Therapy in Treating Patients with Prostate Cancer

    This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer. Hormone therapy such as antiandrogen therapy may fight prostate cancer by blocking the production and interfering with the action of hormones. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Neutron radiation therapy uses high energy neutrons to kill tumor cells and shrink tumors. It is not yet known whether antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy may work better in treating patients with prostate cancer.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Cognitive Assessment and MRI Program in Identifying Cognitive Effects of Androgen Receptor Directed Therapies in Patients with Advanced Prostate Cancer

    This clinical trial studies how well cognitive assessment and magnetic resonance imaging (MRI) program work in identifying cognitive effects of androgen receptor directed therapies such as abiraterone acetate and enzalutamide in patients with prostate cancer that has spread from where it started to other places in the body. Cognitive assessment and MRI program may help to assess the cognitive function of patients during treatment and identify genetic variations that might make patients more or less sensitive to cognitive changes during treatment for prostate cancer.
    Location: 5 locations